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Abstract. Combination therapies are widely accepted as a cornerstone for treatment of
different cancer types. A tumor growth inhibition (TGI) model is developed for combinations
of cetuximab and cisplatin obtained from xenograft mice. Unlike traditional TGI models,
both natural cell growth and cell death are considered explicitly. The growth rate was
estimated to 0.006 h−1 and the natural cell death to 0.0039 h−1 resulting in a tumor doubling
time of 14 days. The tumor static concentrations (TSC) are predicted for each individual
compound. When the compounds are given as single-agents, the required concentrations
were computed to be 506 μg · mL−1 and 56 ng · mL−1 for cetuximab and cisplatin,
respectively. A TSC curve is constructed for different combinations of the two drugs, which
separates concentration combinations into regions of tumor shrinkage and tumor growth.
The more concave the TSC curve is, the lower is the total exposure to test compounds
necessary to achieve tumor regression. The TSC curve for cetuximab and cisplatin showed
weak concavity. TSC values and TSC curves were estimated that predict tumor regression for
95% of the population by taking between-subject variability into account. The TSC concept
is further discussed for different concentration-effect relationships and for combinations of
three or more compounds.
KEY WORDS: mixture dynamics; model-based drug development; oncology; pharmacokinetic-
pharmacodynamic modeling; tumor xenograft.
INTRODUCTION
Combination therapy plays a signiﬁcant role in pharma-
cotherapy (1). One important aspect of combination therapy
is the potential for synergistic effects. Other beneﬁts com-
pared to single-agent treatment include higher overall efﬁ-
cacy, lower exposure to the drugs and thereby improved
safety, reduced toxicity, and lower risk of developing drug
resistances (2–5).
Establishing synergies, ﬁnding the most effective anti-
cancer drug combinations, and optimizing dosing schedules
are all challenging tasks. Mathematical modeling has proved
to be a valuable tool that addresses these challenges and can
be used to quantify and predict the impact of drug combina-
tions on tumor growth dynamics (6,7).
Different data-driven tumor models have been suggested
(8,9). One of the most commonly applied experimental
models is the tumor growth inhibition (TGI) model (10–13).
The TGI model balances model complexity with data
availability. In particular, the TGI model maintains a semi-
mechanistic foundation while having few enough system and
drug parameters for the model to still be calibrated using
experimental data. A theoretical foundation for the TGI
model has also been established by deriving the model from
basic probabilistic assumptions in both single-agent and
combination therapy settings (14,15).
The TGI model divides cancer cells into two categories:
proliferating or damaged. The model consists of a main
compartment representing the proliferating cancer cells and a
number of damage compartments which cells irreversibly
traverse before dying. The drug action of an anticancer
compound is said to be cytostatic and/or cytotoxic. Cytostatic
drug action acts on the proliferating cells by inhibiting
proliferation (cell growth), whereas cytotoxic drug action
stimulates cell death by triggering apoptosis. The TGI model
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can be generalized to combination therapy with two or more
cytostatic and/or cytotoxic compounds. There have been
several reported successes of this (16–20).
Several general methods have been established to
evaluate drug combinations (21–24). A graphical tool is the
isobologram (25–28). The isobologram is based on the
simpliﬁed model of a direct relationship between drug dose
and a biomarker response and generates a Bcurve of
additivity^ which can be used to distinguish additivity from
synergy. A typical isobologram is shown in Fig. 1. Although
depicted as such here, isobolographic curve of additivity need
not be a straight line (29). The isobologram does not take into
account the drug response, nor cancer-speciﬁc information
that a TGI model can provide.
A TGI model is developed for individual exposure to
combinations of cetuximab and cisplatin for the treatment of non-
small cell lung cancer. These compounds are clinically relevant and
have been tested together on various cell lines aswell as in the clinic
(30,31). Themodel assumes that the compounds act independently
of each another. The model is an extension of the standard TGI
models in that it incorporates natural cell death. A consequence of
this is that the initial tumor volume should be distributed
appropriately among the main and damage compartments. The
model is mechanistically attractive, since it discriminates between
natural cell death and increased kill rate by means of chemical
intervention. We further investigate conditions for tumor stasis
based on the model equations for both the single-agent treatments
and the combination therapy. This results in the derivation of what
is deﬁned as the tumor static concentration (TSC) value and, for
combinations of two compounds, the tumor static concentration
curve. The TSC value of a single compound is the plasma
concentration of that compound required to maintain the tumor
in stasis. Such values have been obtained for TGI models (12,32).
The TSC curve is a generalization of the TSC value when two
compounds are given together (33,34). Instead of a single TSC
value, the TSC curve consists of all concentration pairs which give
tumor stasis when present simultaneously.Moreover, we showhow
the curvature of the TSC proﬁle has a large impact on the resulting
tumorgrowth and total exposure to test compounds. In particular, a
highly concave1 (i.e., curving downward) TSC curve will allow for
tumor regression even with a reduced total drug exposure.
Additionally, by taking between-subject variability into account,
we show that it is possible to obtain TSC curves for speciﬁc
individuals from the experimental data. This also makes it possible
to construct a TSC curve of concentration pairs for which a large




Patient-derived xenograft data consisted of 40 tumor-
bearing female nude-nu mice used in a combination therapy
experiment with the anticancer compounds cetuximab and
cisplatin to treat non-small cell lung cancer. These data have
previously been published by Amendt et al. (35).
The 40 mice were divided evenly into four treatment arms:
vehicle, single-agent treatment with cetuximab, single-agent treat-
ment with cisplatin, and combination treatment with both
cetuximab and cisplatin. Treatment was started when tumors
became palpable (with sizes around 80–200mm3). All treatment
arms were given intraperitoneal doses on days 0, 3, 7, 10, and 14
and the doses were always 30mg/kg for cetuximab and 5mg/kg for
cisplatin. The mice in the combination arm were given doses of
both drugs on each day of dosing. Tumors were measured by
caliper on days 0, 3, 7, 10, 14, 17, 21, 24, and 28.
Drug Exposure Models
Since there were no available exposure data for either
cetuximab or cisplatin, pharmacokinetic models were taken from
literature for both compounds. To describe cetuximab exposure, a
one-compartment pharmacokinetic model with ﬁrst-order absorp-
tion kinetics was used, with the explicit solution
Ccetuximab ¼ kaFDV ka−keð Þ e
−ket−e−kat
  ð1Þ
where ka is the absorption rate, ke the elimination rate, D the
dose of cetuximab, F the bioavailability, and V the distribu-
tion volume (36). This model is shown in Fig. 2 (left).
To describe total cisplatin exposure, a two-compartment
pharmacokinetic model with ﬁrst-order absorption kinetics was
used. Themodel is described by the following systemof differential























Fig. 1. The isobolographic curve of additivity (blue). An experimen-
tally observed effect above or below this curve is indicative of a
synergistic or antagonistic relationship between the two drugs,
respectively 1 Although mathematically the curve is said to be convex
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dAp
dt





The initial conditions of the gut, central, and peripheral
compartments are
Ag 0ð Þ ¼ D; Ap 0ð Þ ¼ 0; At 0ð Þ ¼ 0 ð4Þ
where ka is the absorption rate, D the dose, F the bioavailability,
and k10, k12, and k21, the microconstants. Here, Ag, Ap, and At
denote the amount of cisplatin in the gut, plasma and tissue,
respectively. An illustration of this model is shown in Fig. 2 (right).
The total plasma concentration of cisplatin is then given by
Ccisplatin ¼ ApVC ð5Þ
where VC denotes the volume of the central compartment.
Tumor Growth Inhibition Model
A TGI model with cetuximab as a cytostatic and
cisplatin as a cytotoxic drug was used to describe the data
in the ﬁnal model. Modeling of each drug as cytostatic/
cytotoxic was tested using both linear and nonlinear
functions. The ﬁnal selection was made based on AIC.
Drug action was assumed to be independent. An illustra-
tion of this model is given in Fig. 3. The corresponding
system of differential equations is
dV1
dt







Here V1 is the main compartment of proliferating
cancer cells, V2, V3, and V4 are the damage compartments
that cells must go through before dying, kg is the growth
rate, and kk is the (natural) death rate. The inhibitory drug
action, I, of cetuximab was described using an Emax-function
and the stimulatory drug action, S, of cisplatin was
described using a linear function
I Ccetuximabð Þ ¼ 1− ImaxCcetuximabIC50 þ Ccetuximab
S Ccisplatin
  ¼ 1 þ b Ccisplatin ð7Þ
where Imax is the maximum inhibition cetuximab can accom-
plish, IC50 is the concentration of cetuximab required to
obtain 50% of the maximum inhibition, and b is a pharma-
codynamic parameter of cisplatin. The total tumor volume
Fig. 2. (left) Pharmacokinetic model for cetuximab with gut and plasma compartments. The parameters ka and ke represent the drug
absorption and elimination rates, respectively. (right) pharmacokinetic model for cisplatin with gut, plasma, and tissue compartments. The
parameter ka represents the absorption rate and k12, k21, and k10 are the microconstants
ExposureA











Fig. 3. TGI model for combination therapy with independent drug action. Cetuximab (A) inhibits cell proliferation, whereas cisplatin
(B) stimulates cell apoptosis. The kg and kk parameters represent the natural cell kill and death rates, respectively
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Vtotal comprises both V1 and the compartments representing
dying cells.
Vtotal ¼ V1 þ V2 þ V3 þ V4 ð8Þ
Initial Conditions for the TGI Model
An important question is how to distribute the initial tumor
volume among the different compartments V1, V2,V3, and V4.
Without natural cell death, the usual thing to do is to put all of the
initial volume into the main compartment V1. However, with
natural cell death included, this would neglect that cells have been
dying since before treatment was started and one would therefore
expect some cells to be in V2 to V4.
It is possible to show that, starting from any distribution of
the total initial tumor volume into V1 and V2 to V4, the ratio
between two neighboring compartments, (i.e., Vi/Vi − 1) will
approach a constant. If one assumes that the tumor has already
existed for a long time before treatment started, it would make
sense to also assume that this stage has been reached. Therefore,
a reasonable choice of initial conditions is given by
V1 0ð Þ ¼ V0; V2 0ð Þ ¼ V0 kkkg
 
; V3 0ð Þ ¼ V0 kkkg
 2





where V0 is the initial volume of V1. For a detailed derivation
of the initial conditions, see Appendix 1.
Deriving Tumor Static Concentrations
Consider the individuals treated with cetuximab alone.
Since tumor regression is often a treatment goal, we would
like to determine plasma concentrations resulting in tumor
shrinkage. This is done by determining the drug concentra-
tion for which the input and output of each compartment is in
balance. Plasma concentrations above this level may then be
assumed to give tumor shrinkage.2 For the cetuximab
treatment, this means that each right-hand side in Eq. 6
should be zero, but since V2 to V4 only act to delay the death
process, we only need to consider V1. For single-agent













−kk ¼ 0 ð11Þ
since the volume of the main compartment V1 will not be zero
unless the tumor is already eradicated. Equation 11 can be solved




kk− 1−Imaxð Þkg ð12Þ
This concentration is deﬁned as the tumor static concentration
(TSC) value of cetuximab. The TSC value holds for any tumor
volume and at any point in time. Therefore, to ensure tumor
shrinkage over time, plasma exposure above TSC should be
established. ATSC value for cisplatin can be derived in a similar
manner. When Ccetuximab = 0 the condition for stasis becomes
kg−kk 1þ bCcisplatin
  ¼ 0 ð13Þ
which can be simpliﬁed to
Ccisplatin ¼ kg−kkb kk ð14Þ
Tumor Static Concentrations for Combinations
An analysis similar to that for the single-agent compounds can
be performed for the treatment arm that receives both compounds.






  ¼ 0 ð15Þ
This equation describes a curve in the concentration plane
with Ccetuximab and Ccisplatin along the coordinate axes. In this case
one can solve for Ccisplatin to obtain








Equation 16 describes a curve of concentration pairs
(Ccetuximab, Ccisplatin). Any concentration pairs located above
this curve will give tumor shrinkage, whereas concentration
pairs located below the curve will give tumor growth. Equa-
tion 16 is therefore introduced as the TSC curve. The points of
intersection with the coordinate axes are the TSC values derived
for the individual compounds. The TSC curve is valid for any
tumor volume and at any time point. To ensure tumor shrinkage
over time, dosing should be such that the concentration pair
(Ccetuximab, Ccisplatin) is kept above the TSC curve at all times. An
illustration of what a TSC curve could look like is given in Fig. 4.
How the TSC concept is generalized to three or more
compounds is discussed in Appendix 2.
Computational Methods
Nonlinear mixed-effects modeling of the cetuximab and
cisplatin pharmacodynamic data was performed with a ﬁrst-order
conditional estimation (FOCE) method, using a computational
2 The assumption that drug effect increases with concen-
tration is true for most concentration-effect relationships
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framework developed at the Fraunhofer-Chalmers Research
Centre for Industrial Mathematics (Gothenburg, Sweden) and
implemented in Mathematica 10 (Wolfram Research) (38). The
model was evaluated based on individual ﬁt, residual analysis,
visualizations of Empirical Bayes Estimates, and the Akaike
information criterion.
To validate the assumption of independent drug action, a
separate set of parameter estimates were obtained by omitting the
combination arm. Then, a visual predictive check (VPC) was
performed by using these estimates to simulate n = 5 000
individuals given the combination treatment and comparing the
5th and 95th quantiles to the actual observations.
To generate a TSC curve for which 95% of the population is
expected to show tumor regression, a Monte Carlo simulation was
performed. The between-subject variability information contained
in the covariance matrix Ω was used to simulate TSC curves for
1000 hypothetical individuals. The 95% TSC curve was then
selected as the 95th percentile of the simulated curves.
RESULTS
Drug Exposure Models
Parameter estimates for the pharmacokinetic models of
cetuximab and cisplatin were taken from the literature (36,37).
The parameter values used for the cetuximab model (Eq. 1)
were ke= 0.017 h
− 1, ka= 0.44 h
− 1, F= 1, and V=0.094 mL · kg−1.
The corresponding exposure proﬁle is shown in Fig. 5 (left).
The parameter values used for the cisplatin model (Eqs. 2–4)
were ka= 42 h
− 1, k10 = 1.3 h
− 1, k12 = 3.3 h
− 1, k21 = 1.12 h
− 1, F= 1,
and Vp= 377 mL ⋅ kg− 1. The corresponding exposure proﬁle is
shown in Fig. 5 (right).
Tumor Growth Inhibition Model
A population pharmacodynamic model was constructed by
letting the parameters kg and V
0 have lognormally distributed
between-subject variability. A sample of the individual ﬁt for each
treatment arm is given in Fig. 6. Visual predictive checks for all for
treatment arms can be found in Appendix 3.
The parameter estimates for the tumor model are shown in
Table I. The estimated net growth rate is given by kg− kk=
0.0021 h− 1 corresponding to a doubling time of 330 h or 14 days.
When the estimated volume of themain compartment of 60mm3 is
used, the total initial volume is computed to be









which gives an estimate of 140 mm3.
The parameter value of Imax was set to 1 in the ﬁnal model.
The estimated IC50 value for cetuximab of 994 μg ·mL
−1 may be
compared to the maximum exposure of 400 μg ·mL−1 which
corresponds to roughly 30% inhibition of cell proliferation. The
estimated pharmacodynamics parameter of cisplatin is 0.0093mL ⋅
ng− 1. and could be compared to themaximumcisplatin exposure of
104 ng ·mL−1 which increases the kill rate by a factor of 100,
although such levels of exposure only occurred during very short
time periods (see Fig. 5). The model assumption of independent
drug action was validated by a visual predictive check for the
combination arm (see Appendix 4).
Tumor Shrinkage
Tumor Growth














Fig. 4. Schematic of a TSC curve (solid curve) for combination
therapy with two compounds A and B. Reference straight line
(dashed). Concentration pairs (CA,CB) above the curve (green
shaded area) give tumor shrinkage, whereas concentration pairs
below (red shaded area) give tumor growth
C C
Fig. 5. (left) Drug exposure for cetuximab. The orange line indicates the IC50 estimate for cetuximab, and the green line the estimated TSC
value for cetuximab. (right) Drug exposure for cisplatin. The orange line indicates the estimated plasma concentration required to double the
death rate (given by 1/b), and the green curve the TSC value for cisplatin. Dosing was repeated for both compounds on days 0, 3, 7, 10, and 14
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TSC Curve of Cetuximab-Cisplatin
Recall that from the tumor model, we derived Eq. 16 for
the TSC curve. Using the parameter estimates from Table I,
the TSC curve was computed, as depicted in Fig. 7. The
individual TSC values were computed to be TSCCetuximab =
506 μg · mL−1 and TSCcisplatin = 56 ng · mL
−1. The TSC curve
shows a slight deviation from a straight line. Individual TSC
curves were constructed by taking between-subject variability
into account. These are shown in blue in Fig. 8. The dashed
red TSC curve, obtained by Monte Carlo simulation,
indicates expected concentrations required for 95% of the
population to experience tumor shrinkage.
Four Cases of TSC Curves for Independent Drug Action
While there are many ways to incorporate drug interac-
tion into a tumor growth model, the number of models with
independent action is considerably smaller and therefore
easier to investigate. Consider the tumor model in Eq. 6 with
two generic compounds A and B. The corresponding
equation for the TSC curve reads
I CAð Þkg−S CBð Þkk ¼ 0 ð18Þ
We shall consider four cases depending on how I(CA)
and S(CB) are chosen. In all four cases, the TSC equation can
be written in the form
αCACB þ βCA þ γCB ¼ δ ð19Þ
where α, β, γ, and δ are constants which depend on both the drug
and the system parameters. The individual TSC values can then be
expressed as




Linear Inhibition and Linear Stimulation
When both the cytostatic drug action and the cytotoxic
drug action are assumed linear
I CAð Þ ¼ 1−a CA; S CBð Þ ¼ 1þ bCB ð21Þ
the resulting TSC curve will also be linear and can be
rearranged to
kga CA þ kkb CB ¼ kg−kk ð22Þ
which is a straight line passing through the individual TSC
values.
Nonlinear Inhibition and Linear Stimulation
In the second scenario, the cytostatic drug action is of Emax-
























Fig. 6. Representative time courses of observed (symbols) tumor
volumes (mm3) for each of the four treatment arms. The solid lines
represent the tumor volumes ﬁtted by the TGI model
Table I. Parameter Estimates for the Model Describing the Cetuximab and Cisplatin Combination Therapy
Parameter Population median (RSE%) Between-subject variabilitya (RSE%)
kg(h
− 1) 0.0060 (11) 0.10 (23)
kk(h
− 1) 0.0039 (17) –
V0(mm3) 60 (8) 0.33 (12)
IC50(µg ⋅mL− 1) 994 (42) –
Imax 1 (ﬁxed) –
b (mL ⋅ ng− 1) 0.0093 (30) –
σb 27 (4) –
cov(kg, V
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I CAð Þ ¼ 1− ImaxCAIC50 þ CA ; S CBð Þ ¼ 1þ b CB ð23Þ
The TSC equation can be shown to be





The ﬁrst term is nonlinear in CA and CB and will provide
curvature to the TSC curve. This case was illustrated in the
cetuximab-cisplatin example above.
Linear Inhibition and Nonlinear Stimulation
The third case has the roles reversed—the cytostatic drug
action is now linear, while the cytotoxic drug action is of
Emax-type with unit sigmoidicity
S CAð Þ ¼ 1−a CA; S CBð Þ ¼ 1þ SmaxCBSC50 þ CB ð25Þ
The corresponding TSC equation becomes





Nonlinear Inhibition and Nonlinear Stimulation
Lastly, both the cytostatic drug action and the cytotoxic drug
action are assumed to be nonlinear of Emax-type with unit
sigmoidicity
S CAð Þ ¼ 1− ImaxCAIC50 þ CA ; S CBð Þ ¼ 1þ
SmaxCB
SC50 þ CB ð27Þ
The corresponding TSC equation is similar to the previous
two cases, albeit with slightly more complicated terms
1þ Smaxð Þkk− 1−Imaxð Þkg
 
CACB
þ SC50 kk− 1−Imaxð Þkg
 





Impact of the TSC Curve on Tumor Growth
To illustrate the impact of different TSC curves, two
hypothetical curves with the same individual TSC values but
different curvatureswere constructed based on the nonlinear-linear
TSC equation (Eq. 24). The two curves are depicted in Fig. 9 (left)
with their corresponding parameter values listed inTable II. Tumor
volume time courses were simulated assuming a constant plasma
concentration of each drug at three different levels: (A) 0.3 μg ·
mL−1, (B) 0.4 μg ·mL−1, and (C) 0.5 μg ·mL−1. The different time
courses are shown in Fig. 9 (right).As expected, the tumor volumes
are much lower for the blue curves than for the red, since the
























Fig. 7. TSC curve for cetuximab-cisplatin combinations (blue, bold)
distinguishing between regions of tumor growth (light red) and tumor
shrinkage (light green). Reference straight line connecting the
individual TSC values (black, dashed)
C
C
Fig. 8. Individual TSC curves (blue) for the cetuximab-cisplatin combina-
tion therapy, taking into account between-subject variability in the growth
rate kg. The TSC curve for the median individual from Fig. 7 is shown as a
solid red curve. The dashed red line represents a region below which 95%of
the population is expected to show tumor regression
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DISCUSSION
Drug Exposure Models
Since there were no available exposure data for either
cetuximab or cisplatin, models were taken from literature.
For this reason, relatively simple models were chosen to give
a rough estimate of what the exposure could have looked
like. A disadvantage with this approach is that all individuals
are assumed to have identical exposure proﬁles; there is no
between-subject variation. This could lead to situations where
actual variability in kinetic parameters is falsely attributed to
variations in dynamic parameters, e.g., a large-growing tumor
that was due to low drug exposure, could instead be falsely
explained by the model with an unreasonably large growth
rate parameter or low potency drug.
Tumor Growth Inhibition Model
A TGI model with independent drug action between
cetuximab and cisplatin proved sufﬁcient to explain the combina-
tion arm and no investigation into possible interaction terms was
necessary. Since exposure proﬁles and models were taken solely
from the literature, an assumption of no interaction on exposure
level was implied. All parameters in Table I except for IC50 were
estimated with acceptable precision and were located within
biologically reasonable ranges. The relatively poor precision for
IC50 is due to the estimated value of 994 μg ·mL
−1 is well above the
maximum drug exposure at around 400 μg ·mL−1 and themodel is
therefore insensitive to changes in IC50. The between-individual
variation was large for both the growth rate and initial tumor
volume, which is due to the variability between subjects in the
vehicle arm. It is also possible that some of the between-subject
variability in growth rate is actually due to different levels of
epidermal growth factor receptor expression (EGFR), which has
been suggested to be associated with the drug effect of cetuximab
(35). In the TGI model, individuals with a high EGFR expression
would therefore be given a larger growth rate than thosewith a low
EGFRexpression. The parameter estimateswhen the combination
armwas removed (Table III)were very similar to before, indicating
that the combination arm is well-explained by the zero-interaction
model. This is further validated from the visual predictive check in
Fig. 10 (Appendix 3)which shows that almost all observations from
the combination arm fall within the estimated 90% conﬁdence
intervals obtained using Table III.
The TGI model incorporates a natural cell death rate kk
which was successfully estimated. However, it should be noted
that the vehicle model alone is not identiﬁable; one can only
determine the net growth rate kg − kk. However, with the
presence of a drug, these parameters can be separated and
were estimated with good precision. This is made possible by an
underlying assumption that the natural and drug-induced death
processes are equivalent in a modeling sense, which is consistent
with our viewpoint of cisplatin stimulating an already existing
death process as opposed to induces a new one.
TSC Curve for Cetuximab-Cisplatin
The TSC curve is visually similar to the well-established
isobologram (26,27), but with doses along the coordinate axes
Fig. 9. (left) Two different TSC curves (blue and red) and (right) the corresponding growth dynamics assuming a constant drug infusion of
each drug at three concentration levels (A, B, and C)
Table II. Parameter Values Used to Construct the Two TSC Curves
in Fig. 9 (Blue and Red)
Parameter Value (blue) Value (red)
kg(h
− 1) 0.0125 0.0125
kk(h
− 1) 0.0042 0.0042
V0(mm3) 100 100
IC50(µg ⋅mL− 1) 0.05 0.5
Imax 0.7 1.0
b (mL ⋅ ng− 1) 2.0 2.0
463Tumor Static Concentration Curves
replaced with drug plasma concentrations, and the considered
effect is when the net growth rate is zero.While the isobologram is
typically based on a dose-effect model ofEmax-type, the TSC curve
is obtained from an exposure-driven growth model.
The TSC curve derived from cetuximab-cisplatin data serves
as a practical example. The TSC curve exhibited a slight curvature,
indicating that the drug combination effect is weakly synergistic.
This is an interesting result given previous claims that EGFR
inhibitors should act antagonistically with chemotherapy, although
it is here limited to only one study of one speciﬁc combination (39).
The certainty of the weak synergy is further explored in
Appendix 5.
It is possible to derive TSC curves for more complicated
growth functions than the exponential one used here. The
Gompertz, logistic, and Simeoni growth functions (9,12) all start
with an exponential growth phase which slows down as the tumor
grows large. ATSC curve can then be derived by assuming that the
tumor maintains its initial exponential growth. This is a necessary
approximation, since we want the concentration pairs above the
TSCcurve to give tumor shrinkage for all tumor volumes, including
those in the initial exponential phase.
The individual TSC curves in Fig. 8 show that there can
be signiﬁcant variation in which concentrations will be needed
for tumor shrinkage. It is necessary to take between-subject
variability into account and construct and simulate individual
TSC curves. One can then target concentrations above the
TSC curve for, e.g., 95% of the population (dashed, red).
In Fig. 8, the individual TSC curves are non-intersecting.
This is not true in general and would typically only occur when
only one parameter has population variability (in this case kg). If
two or more parameters have between-subject variability, some
of the individual TSC curve would be expected to intersect
unless the parameters are highly correlated.
Four Cases of TSC Curves for Independent Drug Action
We outlined four standard cases of independent drug action
between a cytotoxic drug and a cytostatic drug. The ﬁrst important
observation is that the case with linear inhibitory drug action and
linear stimulatory drug action is the only case where the TSC curve
becomes a straight line (signiﬁedbyα= 0) indicating additivity. This
straight line means that the concentration-effect relationship is
linear even when the drugs are combined. There are no beneﬁts
from combining the drugs. In contrast, when either the inhibition or
stimulation is nonlinear, or both are nonlinear, the TSC curve will
also be a nonlinear curve falling below the straight line connecting
the individual TSC values. It will then be possible to decrease the
total exposure levels of both compounds and still obtain tumor
shrinkage.Evenwith twodrugswhichwhengiven individually each
require a concentration of 100μg ·mL−1 to be above theTSCvalue
a sufﬁciently curved TSC curved may tell us that tumor shrinkage
can be obtained with a concentration of 25 μg ·mL−1 of each drug
when given together. If the TSC curve were a straight line, the
required concentrations would instead have been 50 μg ·mL−1 of
each drug.
None of the four cases studied allow for antagonism, or an
outward curving TSC curve. To allow for antagonism, the most
common way would be to include an explicit (negative) interaction
term added to the TGI model, which would contribute to making
Table III. Parameter Estimates for the Model Describing the Cetuximab and Cisplatin Combination Therapy, Using Only the Vehicle and
Single-Agent Treatment Arms
Parameter Population median (RSE%) Between-subject variability (RSE%)
kg(h
− 1) 0.0065 (13) 0.10 (23)
kk(h
− 1) 0.0044 (19) –
V0(mm3) 59 (8) 0.32 (9)
IC50(µg ⋅mL− 1) 1139 (50) –
Imax 1 (ﬁxed) –
b (mL ⋅ ng− 1) 0.0074 (31) –
σa 30 (5) –
cov(kg, V
























Fig. 10. A VPC for the combination arm using the parameter
estimates from Table III. The solid lines indicate the simulated 5th,
50th, and 95th percentiles. Colored dots represent different observed
individuals in the combination arm
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the parameter α in Eq. 19 negative and result in an antagonistic
TSC curve.
Impact of the TSC Curve on Tumor Growth
We also investigated the relationship between the TSC
curve and tumor growth dynamics. We showed in Fig. 9 that
even if the individual TSC values are the same, the shape of
the TSC curve is very important to how rapidly the tumor
volume changes. Since we have assumed that the drugs do not
interact, the different growth dynamics shown in Fig. 9 must
originate from the nonlinear concentration-response relation-
ship of the inhibitory function I(CB). In particular, what
ultimately decides why the blue TSC curve performs better is
how well the drugs perform at exposure levels well below
TSC. That the drugs have higher efﬁcacy in the blue curve
than in the red curve at concentrations lower than the TSC
value is translated into the blue TSC curve exhibiting larger
curvature than the red.
Extensions and Future Work
Since we focused on introducing the TSC curve and
providing several examples under zero-interaction hypothe-
ses, a natural next step would be to explore how the TSC
curve changes with the inclusion of (natural) synergy/
antagonism terms. Synergy terms should increase the concav-
ity of the TSC curve, while antagonism should have the
opposite effect and make it more convex. Future work will
also need to explore the validity and utility of the TSC
approach, for example by using independent data sets.
CONCLUSIONS
The concept of a TSC curve for drug combinations in
tumor growth models is derived and applied to an in vivo
dataset. The TSC curve provides three important pieces of
information. First, it gives minimal concentration pairs
needed to achieve tumor shrinkage. Second, the shape of
the TSC curve indicates how well the compounds work in
combination, in the sense that a highly concave TSC curve
indicates that it is possible to reduce the total drug exposure
and still obtain tumor shrinkage. Third, the TSC curve can be
used to optimize dosing regimens by maintaining concentra-
tions above the curve as much and for as long as possible.
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APPENDIX 1
Consider the unperturbed tumor model incorporating
natural cell death, with main compartment V1 and damage










¼ kkVi−1−kkVi; 3≤ i≤n
ð29Þ




where v = (V1,…, Vn) is the n-dimensional vector of volumes
and the n × n-matrix A is deﬁned by
kg−kk 0 ⋯ 0 0
kk −kk ⋯ 0 0
⋮ ⋮





Since A is a triangular matrix, its eigenvalues can be
found on the diagonal
λ1 ¼ kg−kk; λ2 ¼ λ3 ¼… ¼ λn ¼ −kk ð32Þ
Fig. 11. A VPC for each of the four treatment arms using the
parameter estimates from Table I. The solid lines indicate the
simulated 5th, 50th, and 95th percentiles. Colored dots represent
different observed individuals in the combination arm
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The corresponding eigenvectors are given by








; w2 ¼ 0;…; 0; 1ð Þ ð33Þ
The solution to Eq. 29 is then given by a linear
combination of the n independent solutions
w1eλ1t; w2eλ2t ð34Þ
and










n−1ð Þ! w2 þ…þ w2;n
  ð35Þ
where the vectors w2,k are so-called generalized eigenvectors
of the matrix A, which for this particular problem can be
shown to be
w2;2 ¼ 0; 1; 0; …; 0ð Þ; w2;3 ¼ 0; 0; 1; 0; …; 0ð Þ; …;w2;n
¼ 0; 0; 0; …; 1ð Þ ð36Þ
As t grows large, eλ2 t ¼ e−kkt goes to zero. Therefore, for
sufﬁciently large t, the solution to Eq. 29 is described only by the
ﬁrst solution
v tð Þ ¼ w1e kg−kkð Þt ð37Þ
Hence, the tumor will grow exponentially with rate param-
eter λ1 and a constant proportion between the compartments
governed by w1.
APPENDIX 2
It is in theory possible to generalize the TSC
construction to treatments with three or more compounds
by following the same steps. We know that a treatment
with a single compound gives a point (the TSC value) in
ℝ and a combination of two compounds gives a curve (the
TSC curve) in ℝ2. Likewise, a combination of three
compounds will give a surface (the TSC surface) in ℝ3,
and, in general, a combination of n compounds will give
an (n − 1)-dimensional hypersurface in ℝn.
To show one higher-dimensional example, imagine a
treatment with n independent cytotoxic compounds with
concentrations C1,…, Cn and each with a linear stimulatory
function
Si Cið Þ ¼ aiCi; 1≤ i≤n ð38Þ
with different potency parameters ai. The differential







kkSi Cið ÞV1 ð39Þ




kkSi Cið Þ ¼ 0 ð40Þ
In particular, for n = 3 this gives an equation on the form
a1C1 þ a2C2 þ a3C3 ¼ kgkk ð41Þ
which can be recognized as the equation of a plane in ℝ3.
APPENDIX 3
Using the parameter estimates in Table I, a VPC was
performed for each of the four treatment arms as shown in
Fig. 11. The ﬁgure indicates that all treatment arms were
adequately predicted by the model.
APPENDIX 4
To validate the assumption of independent drug
action, a separate set of parameter estimates were
obtained by omitting the combination arm (see Table III).
Then, a VPC was performed by using these estimates to
simulate n = 5000 individuals given the combination treat-
ment and comparing the 5th and 95th quantiles to the
actual observations. The resulting VPC is shown in Fig. 10.
With approximately 10% of the observations outside the
shaded region, the assumption of independent drug action
cannot be rejected.
APPENDIX 5
To study the certainty of the weak synergy between
cetuximab and cisplatin, a Monte Carlo simulation was
performed to construct TSC curves consistent with the
relative standard errors reported for the parameters in
Table I. To evaluate whether such a curve was sufﬁciently
curved, the ratio between the areas under the TSC curve and
the reference line was computed, yielding values ranging from
zero to one. If the ratio was below 0.9, the TSC curve was
regarded as sufﬁciently curved to indicate (at least) weak
synergy. A total of 99.4% of the simulated TSC curves
showed weak synergy, indicating that the claim of weak
synergy is well-founded.
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